Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calcium Folinate in Spastic Paraplegia 56
NCT06478238Phase 1Recruiting
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Jul 2024
- Primary completion
- May 2030
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of folinic acid in hereditary spastic paraplegia type 56 (HSP56), sponsored by Shanghai Sixth People's Hospital. Primary endpoint: Gross Motor Function Measure-88 at 5 years. Started Jul 2024; status: recruiting.
02
Drugs
folinic acid
03
Conditions
hereditary spastic paraplegia type 56 (HSP56)
Beyond the preview
Go deeper on NCT06478238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06478238.